AOP-Wiki

API

All Key Events

Showing 1 to 25 of 1921 Key Events

ID	Title	Event Component Count	Biological Organization	Created At	Last Updated	AOPs

2428	Gut derived PAMPs, increased Short Name PAMPs, increased	0	Cellular	Apr 23, 2026	Apr 23, 2026	642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2427	Bile acid composition in bile and intestine, altered Short Name Bile acid composition, altered	0	Cellular	Apr 23, 2026	Apr 23, 2026	642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2426	Hepatic BSEP (ABCB11), decreased Short Name BSEP (ABCB11), decreased	0	Cellular	Apr 23, 2026	Apr 23, 2026	642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2425	Intrahepatic bile acid burden, increased Short Name Intrahepatic bile acids, increased	0	Cellular	Apr 23, 2026	Apr 23, 2026	642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2424	Hepatic CYP7A1, increased Short Name Hepatic CYP7A1, increased	0	Cellular	Apr 22, 2026	Apr 22, 2026	642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2423	Hepatic SHP, decreased Short Name Hepatic SHP, decreased	0	Cellular	Apr 22, 2026	Apr 22, 2026	232: NFE2/Nrf2 repression to steatosis
2422	Ileal FGF15/FGF19 secretion, decreased Short Name Decreased FGF15/FGF19	0	Cellular	Apr 22, 2026	Apr 22, 2026	642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2421	Inhibition, Intestinal FXR Short Name FXR inhibition	0	Molecular	Apr 22, 2026	Apr 22, 2026	2 AOPs 642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation 232: NFE2/Nrf2 repression to steatosis
2420	Increased, Retinoic Acid Receptor Activation Short Name Increased, RAR activation	0	Tissue	Apr 22, 2026	Apr 23, 2026	400: Inhibition of CYP26B1 activity in fetal testis leading to reduced fertility
2419	Decreased, Retinoic Acid Receptor Activation Short Name Decreased, RAR activation	0	Tissue	Apr 22, 2026	Apr 23, 2026	398: Decreased ALDH1A (RALDH) activity leading to decreased fertility via disrupted meiotic initiation of fetal oogonia
2418	Increased, phenotypic female-biased sex ratio Short Name Increased, female-biased sex ratio	1	Population	Apr 17, 2026	Apr 17, 2026	641: Activation, estrogen receptor alpha leads to increased, phenotypic female-biased sex ratio via increased, differentiation to ovaries
2417	Increased, differentiation to ovaries Short Name Increased, differentiation to ovaries	1	Individual	Apr 17, 2026	Apr 17, 2026	641: Activation, estrogen receptor alpha leads to increased, phenotypic female-biased sex ratio via increased, differentiation to ovaries
2416	human amyotrophic lateral sclerosis (ALS) Short Name ALS	0	Individual	Mar 30, 2026	Mar 30, 2026	636: Increase in reactive oxygen species (ROS) leading to human amyotrophic lateral sclerosis (ALS)
2415	Precocious puberty Short Name Precocious puberty	1	Individual	Mar 26, 2026	Mar 26, 2026	639: Activation, estrogen receptor alpha leads to precocious puberty via increased kisspeptin release
2414	COL3A1 Signaling Pathway Short Name COL3A1 Signaling Pathway	0	Molecular	Mar 25, 2026	Mar 25, 2026	638: Co-exposure to microplastics and cadmium leading to progression from NAFLD to liver tumorigenesis
2413	Increased, uterine weight Short Name Increased, uterine weight	1	Organ	Mar 13, 2026	Mar 13, 2026	637: Activation, estrogen receptor alpha leads to increased uterine weight via earlier proliferation of cells of the uterine lining
2412	Increase, Hepatic intracellular active glucocorticoids Short Name	0	Cellular	Feb 18, 2026	Feb 26, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2411	Increase, Circulating active glucocorticoid availability Short Name	0	Organ	Feb 18, 2026	Feb 24, 2026	None
2410	Increase, 11β-Hydroxysteroid dehydrogenase type 1 activity Short Name Increase, 11β-HSD1 activity	0	Molecular	Feb 18, 2026	Feb 18, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2409	Decrease, 11β-Hydroxysteroid dehydrogenase type 2 activity Short Name Decrease, 11β-HSD2 activity	0	Molecular	Feb 10, 2026	Feb 26, 2026	630: Decreased 11β-Hydroxysteroid dehydrogenase type 2 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction
2408	Increase, Adipose lipolysis Short Name Increase, Adipose lipolysis	0	Tissue	Feb 10, 2026	Feb 10, 2026	3 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
2407	Increase, Cirrhosis Short Name Increase, Cirrhosis	0	Organ	Feb 10, 2026	Feb 11, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2406	Increase, Regenerative nodule formation Short Name Increase, Regenerative nodule formation	0	Tissue	Feb 10, 2026	Feb 10, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2405	Increase, Hepatocellular lipotoxicity Short Name Increase, Hepatocellular lipotoxicity	0	Cellular	Feb 10, 2026	Feb 10, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2404	Increase, kidney fibrosis Short Name Increase, kidney fibrosis	0	Tissue	Feb 6, 2026	Feb 27, 2026	622: Calcineurin inhibitor induced nephrotoxicity leading to kidney failure